Chinese ship linked to Baltic Sea cable breach resumes voyage
China's Nio introduces Firefly brand to take on BMW's Mini
Top-ranking NYPD officer abruptly resigns amid sexual misconduct allegations
Pope has a cold and will skip outdoor Sunday prayer ahead of a busy week
How Democrats kept leverage by averting a government shutdown, according to analyst
'Source of political stalemates': Smerconish on debt ceiling battle
A pilot raced through the airport to surprise an old friend: the woman who saved his life
Senate passes RFK Stadium land bill, giving the Washington Commanders a major off-the-field win
Tiger Woods says his son Charlie beat him in a round of golf for the first time, but only on a nine hole course
(Reuters) -Germany's Merck on Friday raised its forecast for the group, mainly driven by a strong operating performance at its healthcare and electronics units.
The maker of pharmaceuticals, lab gear and specialty chemicals now expects net sales to be between 20.7 billion euros ($22.49 billion) and 22.1 billion euros for 2024.
The healthcare unit's performance "more than offset the provision equal to a mid-double-digit million euro amount associated with xevinapant", the statement added.
Last month, the company said a clinical trial testing its head and neck cancer drug, xevinapant, would be stopped for lack of efficacy.
For the second quarter, the diversified group reported net sales of 5.4 billion euros and adjusted earnings before interest, income tax, depreciation and amortisation of 1.5 billion euros.
($1 = 0.9204 euros)
(Reporting by Urvi Dugar, Editing by Louise Heavens)
